|
Any evaluation of this stock depends on what happens next. Small company, limited stock, with a must have product. The product is thin tech prep, which is already used by 2000 labs in testing for various kinds of cancer. How many labs are there? Thin tech was developed because the company was researching a computer readable slide, and existing slides were too dirty. Looks like NPTH might lead them to the computer reader. More programming is needed because it still is missing 4+% of the "maybe" slides, but still it can be used for re-reading the slides techies have read as negative. All this makes for a powerful future for cytc. So you can expect some big outfit to come in and merge, or throw money at them to buy, or to fund some hugh research project that transfers lots of stock, etc. Which means large holders will be made very rich and ordinary holders will get a good price which will be considerably less than the stock could grow to. There are 100 million pap smears done each year, and lots of other cancer slides are made, so any other attempt to evaluate what 9 million shares will be worth is pie in the sky foolish. Looks like a good stock. Hang on. jperry@texas.net |
